Support from Traditional Healers to Improve HIV Viral Control in Rural Uganda
Led by Weill Medical College of Cornell University · Updated on 2026-04-20
650
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new approach to support people living with HIV in rural Uganda by training traditional healers to provide counseling, testing, and help with starting antiretroviral therapy quickly. This study aims to see if this additional support can help more people achieve viral suppression compared to standard clinic care. The study is interventional and randomized, focusing on improving health outcomes for people living with HIV in rural areas.
Participants are divided into two groups one receives standard clinic care plus additional support from trained traditional healers using a tailored curriculum for medication adherence, one-on-one counseling, social support, and personalized adherence strategies. The other group receives standard clinic care with no extra linkage or psychosocial support. Both groups are referred to government-run HIV clinics for care.
During the study, participants will have visits at baseline, 12 months, and 24 months with a study nurse and agree to attend one of five designated HIV clinics for care. Researchers will monitor viral load suppression at 12 months as the main outcome. Secondary outcomes include linkage to care, ART initiation within 7 days, adherence, retention in care, and quality of life measured at 12 months. The total study duration extends with follow-ups at 24 months and beyond to assess long-term effects.
CONDITIONS
Brief Title
Omuyambi: Traditional Healer Support to Improve HIV Viral Suppression in Rural Uganda
Research Team
R
Radhika Sundararajan, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Reactive oral swab rapid HIV self-test at the traditional healer location or previously diagnosed with HIV verified by a clinic
CASE adherence index score of 10 or less
Baseline viral load measurement greater than 200 copies/mL
Primary residence in Mbarara or Rwampara district
Agreement to study procedures, including attending one of five predetermined HIV clinics and in-person visits at baseline, 12, and 24 months with a study nurse
You will not qualify if you...
Unwilling or unable to participate in study procedures
Unable to provide written informed consent
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Outpatient Treatment
Duration - 12 months
Participants receive HIV testing, referral, and linkage to care. Those in the intervention arm receive additional adherence support, one-on-one counseling, social support, and individualized adherence strategies with traditional healers.
Baseline visit and follow-up visits at 12 and 24 months
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Traditional healer support to improve HIV viral suppression in rural Uganda (Omuyambi): study protocol for a cluster randomized hybrid effectiveness-implementation trial.
'Empowerment' as a proximal implementation outcome for task shifting with informal cadres: findings from a qualitative study with traditional healers in rural Uganda.